TerminatedNot Applicable

Study of Daclatasvir-based Therapy in Chinese Participants With Chronic Hepatitis C (CHC)

Stopped: Insufficient Enrollment

China3 participantsStarted 2018-05-08

Plain-language summary

Study is a non-interventional, prospective, multicenter post marketing surveillance study to determine the safety of daclatasvir based therapy

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participants 18 years of age and older * Participants with Chronic Hepatitis C virus (CHC) who are eligible for treatment with branded DCV-based therapy as indicated in the locally approved label Exclusion Criteria: * Participants under the age of 18 Other protocol defined inclusion/exclusion criteria could apply

What they're measuring

Number of adverse events (AEs)

Timeframe: Approximately 72 weeks

Number of serious adverse events (SAEs)

Timeframe: Approximately 72 weeks

Trial details

NCT IDNCT03500562

SponsorBristol-Myers Squibb

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2019-03-29

View on ClinicalTrials.gov More Chronic Hepatitis C trials